脑脊液α-突触核蛋白通过种子扩增和 AD 的临床表现聚集。
CSF alpha-synuclein aggregates by seed amplification and clinical presentation of AD.
机构信息
Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy.
Department of Continuity of Care and Frailty, Neurology Unit, ASST Spedali Civili Brescia Hospital, Brescia, Italy.
出版信息
Alzheimers Dement. 2023 Aug;19(8):3754-3759. doi: 10.1002/alz.13109. Epub 2023 Apr 27.
INTRODUCTION
Accumulating evidence suggests that α-synuclein (αSyn) can modulate Alzheimer's disease (AD) pathology. The aim of this study was to evaluate the prevalence and clinical features associated with cerebrospinal fluid (CSF) αSyn detected by seed amplification assay (SAA) in AD.
METHODS
Eighty AD patients with CSF AT(N) biomarker positivity (mean age 70.3 ± 7.3 years) and 28 non-AD age-matched controls were included. All subjects underwent standardized clinical assessment; CSF αSyn aggregates were detected by SAA.
RESULTS
CSF was αSyn-SAA positive (αSyn+) in 36/80 AD patients (45%) and in 2/28 controls (7.1%). AD αSyn+ and αSyn- patients were comparable for age, disease severity, comorbidity profile, and CSF core biomarkers. AD αSyn+ presented a higher prevalence of atypical phenotypes and symptoms.
CONCLUSIONS
Our findings demonstrate that concomitant CSF αSyn pathology is present in a significant proportion of AD patients starting in the early stages and can affect clinical presentation. Longitudinal studies are warranted to evaluate the significance for the disease course.
简介
越来越多的证据表明α-突触核蛋白（αSyn）可以调节阿尔茨海默病（AD）的病理。本研究旨在评估通过种子扩增检测（SAA）检测到的 AD 患者脑脊液（CSF）αSyn 的患病率及其相关的临床特征。
方法
纳入 80 名 CSF AT（N）生物标志物阳性的 AD 患者（平均年龄 70.3±7.3 岁）和 28 名年龄匹配的非 AD 对照组。所有受试者均接受了标准化的临床评估；通过 SAA 检测 CSF αSyn 聚集物。
结果
36/80 名 AD 患者（45%）和 2/28 名对照组（7.1%）的 CSF 为αSyn-SAA 阳性（αSyn+）。AD αSyn+和 αSyn-患者的年龄、疾病严重程度、合并症谱和 CSF 核心生物标志物相似。AD αSyn+患者出现不典型表型和症状的比例更高。
结论
我们的研究结果表明，在早期阶段就存在伴发的 CSF αSyn 病理学的 AD 患者比例相当高，并且可能影响临床表型。需要进行纵向研究来评估其对疾病进程的意义。
Zotero 插件